UPDATE 1-Two drug approvals to boost Glaxo's Japanese sales

(Reuters) - Advair, which is also sold as Seretide, will be marketed under a new name -- Adoair -- in Japan.

It will be the first combination respiratory medicine targeting both inflammation and bronchoconstriction in Japan, though AstraZeneca Plc also hopes to launch its rival two-in-one inhaler Symbicort before too long.


Read more at Reuters.com Government Filings News